Ceregene Elects Raymond Bartus Vice President of Research and Development
Thursday November 14, 7:03 am ET
SAN DIEGO, Nov. 14 /PRNewswire/ -- Ceregene, Inc. today announced that accomplished neuroscientist, Raymond T. Bartus, Ph.D. has been appointed to the new position of vice president of research and development of Ceregene. Dr. Bartus, a pioneer in the neuroscience industry is the co-developer of the Cholinergic Theory of Alzheimer's Disease -- a theory demonstrating the relevance of cholinergic neurons in the disease process of Alzheimer's disease. Dr. Bartus, who brings nearly 30 years of neuroscience expertise to Ceregene, will join the company in late November.
"We are elated to have Ray join our team. His proven leadership, knowledge and expertise is precisely what will enable Ceregene to bring additional products to the clinic," stated Jeffrey M. Ostrove, Ph.D., president and chief operating officer of Ceregene.
Dr. Bartus has built and directed several research teams at both large multi-national pharmaceutical companies and small start-up companies. Under his leadership, his groups have successfully identified and developed novel compounds, many of which have advanced to clinical development. Additionally, Dr. Bartus has maintained a strong scientific presence and continuous academic affiliations during his career, which include adjunct academic appointments and collaborations, editorial responsibility and a publication record involving approximately 200 manuscripts. Dr. Bartus is the founding editor and inaugural editor-in-chief of the scholarly journal, Neurobiology of Aging: Experimental and Clinical Research.
Prior to joining Ceregene, Dr. Bartus served for over 10 years at Alkermes, Inc., most recently as senior vice president, pre-clinical research and development.
"I am truly excited about joining Ceregene. The gene therapy technologies the company is developing to deliver neurotrophic factors to selective brain regions to treat Alzheimer's, Parkinson's and other neurodegenerative diseases are very promising technologies and were an important consideration for me in my decision to join Ceregene. I look forward to helping advance the gene therapies to and through the clinical development process," stated Dr. Bartus.
Ceregene, Inc. is a San Diego-based biotechnology company focused on the development and commercialization of gene therapies for neurological disorders including Alzheimer's disease and Parkinson's disease. Ceregene was launched in January 2001 and is a majority-owned subsidiary of Cell Genesys, Inc. (Nasdaq: CEGE - News), which is headquartered in Foster City, CA.
Statements made herein about Ceregene and Cell Genesys, other than statements of historical fact, including statements about the potential of the company's technologies and nature of product pipelines are forward-looking statements and are subject to a number of uncertainties that could cause actual results to differ materially from the statements made including risks associated with the success of research and development programs, clinical trials, the regulatory approval process for clinical trials, competitive technologies and products, patents, continuation of corporate partnerships and the need for additional financings. For information about these and other risks, which may affect Ceregene and Cell Genesys, please see the Cell Genesys Annual Report on Form 10-K dated April 1, 2002 as well as Cell Genesys' reports on Form 10-Q and 8-K and other reports filed from time to time with the Securities and Exchange Commission.
Make Your Opinion Count - Click Here
--------------------------------------------------------------------------------
Source: Ceregene, Inc. |
